Ligand Pharmaceuticals Inc (NASDAQ:LGND)

53.97
Data as of Oct 24
 -0.16 / -0.30%
Today’s Change
41.99
Today|||52-Week Range
80.42
+2.60%
Year-to-Date
Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog
Oct 24 / Zacks.com
Will Biogen Idec (BIIB) Pull a Surprise this Earnings Season? - Analyst Blog
Oct 20 / Zacks.com
Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog
Oct 24 / Zacks.com
Will Abbott Labs (ABT) Miss on Earnings This Quarter? - Analyst Blog
Oct 20 / Zacks.com
Will Ligand Pharmaceuticals Beat Q3 Earnings Estimates? - Analyst Blog
Oct 24 / Zacks.com
Will Sangamo (SGMO) Incur Wider-than-Expected Q3 Loss? - Analyst Blog
Oct 20 / Zacks.com
Will Amgen (AMGN) Disappoint in the Q3 Earnings Season? - Analyst Blog
Oct 24 / Zacks.com
Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Oct 17 / Zacks.com
Will Vertex Pharmaceuticals (VRTX) Post a Lower Q3 Loss? - Analyst Blog
Oct 24 / Zacks.com
Can Illumina (ILMN) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Oct 16 / Zacks.com
Can Epizyme (EPZM) Surprise This Earnings Season? - Analyst Blog
Oct 24 / Zacks.com
Orexigen Up on $100M Milestone Payment from Takeda - Analyst Blog
Oct 16 / Zacks.com
Ligand (LGND) Shares March Higher, Can It Continue? - Tale of the Tape
Oct 24 / Zacks.com
MannKind (MNKD) Worth Watching: Stock Gains 12.9% - Tale of the Tape
Oct 16 / Zacks.com
Why Earnings Season Could Be Great for Ligand (LGND) - Tale of the Tape
Oct 24 / Zacks.com
GW Pharmaceuticals Down on Disappointing Mid-Stage Data - Analyst Blog
Oct 15 / Zacks.com
Omeros Falls as Enrollment for OMS824 Study is Suspended - Analyst Blog
Oct 23 / Zacks.com
Mallinckrodt Gives FY15 Guidance Post Questcor Acquisition - Analyst Blog
Oct 15 / Zacks.com
Cubist Pharmaceuticals' Q3 Earnings Beat Expectations - Analyst Blog
Oct 23 / Zacks.com
AbbVie Reconsiders Shire Acquisition Due to New Tax Rules - Analyst Blog
Oct 15 / Zacks.com
Vertex Pharmaceuticals' Kalydeco Wins FDA Panel Backing - Analyst Blog
Oct 22 / Zacks.com
Alnylam Reveals Positive Data from its Pipeline Candidates - Analyst Blog
Oct 15 / Zacks.com
Will Bristol-Myers (BMY) Disappoint This Earnings Season? - Analyst Blog
Oct 22 / Zacks.com
Cyclacel Provides SEAMLESS Study Update on Sapacitabine - Analyst Blog
Oct 14 / Zacks.com
Will Agenus (AGEN) Incur Wider-than-Expected Q3 Loss? - Analyst Blog
Oct 22 / Zacks.com
AbbVie's Humira Positive in Late-Stage Skin Disease Study - Analyst Blog
Oct 14 / Zacks.com
Amgen Gains as Third Point Suggests Split - Analyst Blog
Oct 22 / Zacks.com
Pfizer's Breast Cancer Candidate Gets Priority Review - Analyst Blog
Oct 14 / Zacks.com
Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog
Oct 22 / Zacks.com
Alnylam Jumps on Positive Patisiran Data from Phase II Study - Analyst Blog
Oct 14 / Zacks.com
Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog
Oct 22 / Zacks.com
NewLink Genetics (NLNK) Shows Strength: Stock Up 23.7% - Tale of the Tape
Oct 14 / Zacks.com
Orexigen (OREX) Shows Strength: Stock Gains 11.1% - Tale of the Tape
Oct 22 / Zacks.com
Amgen's Blinatumomab Gets Priority Review in the U.S. - Analyst Blog
Oct 13 / Zacks.com
Pacific Biosciences to Incur Narrower-than-Expected Q3 Loss - Analyst Blog
Oct 21 / Zacks.com
Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx - Analyst Blog
Oct 13 / Zacks.com
Will BioMarin (BMRN) Disappoint This Earnings Season? - Analyst Blog
Oct 21 / Zacks.com
Prosensa Starts Rolling NDA Submission for Drisapersen - Analyst Blog
Oct 13 / Zacks.com
Will Alexion (ALXN) Earnings Suffer Due to Higher Costs? - Analyst Blog
Oct 21 / Zacks.com
Targacept's Nine-Year Association with AstraZeneca to End - Analyst Blog
Oct 13 / Zacks.com
Celgene (CELG) Q3 Earnings to Be Overrun by Expenses? - Analyst Blog
Oct 21 / Zacks.com
Will Johnson & Johnson Beat Earnings on Pharma Sales? - Analyst Blog
Oct 13 / Zacks.com
Why Ligand Pharmaceuticals (LGND) Isn't Done Growing Earnings Yet - Tale of the Tape
Oct 21 / Zacks.com
Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5% - Tale of the Ta...
Oct 13 / Zacks.com
Will GlaxoSmithKline (GSK) Earnings Suffer on China Probe? - Analyst Blog
Oct 20 / Zacks.com
 

To view my watchlist

Not a member yet?

Sign up now for a free account

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.